The estimated Net Worth of Thomas J Riga is at least $5.75 Milión dollars as of 14 March 2023. Mr. Riga owns over 49,534 units of Spectrum Pharmaceuticals stock worth over $486,583 and over the last 7 years he sold SPPI stock worth over $1,444,821. In addition, he makes $3,817,960 as Chief Operating Officer, Chief Commercial Officer a Executive Vice President at Spectrum Pharmaceuticals.
Thomas has made over 24 trades of the Spectrum Pharmaceuticals stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 49,534 units of SPPI stock worth $39,627 on 14 March 2023.
The largest trade he's ever made was selling 176,813 units of Spectrum Pharmaceuticals stock on 30 January 2023 worth over $107,856. On average, Thomas trades about 20,134 units every 63 days since 2018. As of 14 March 2023 he still owns at least 472,411 units of Spectrum Pharmaceuticals stock.
You can see the complete history of Mr. Riga stock trades at the bottom of the page.
Thomas J. Riga serves as Chief Operating Officer, Chief Commercial Officer, Executive Vice President of the Company. Mr. Riga has served as our Chief Operating Officer since December 2017, as Executive Vice President since May 2017 and as our Chief Commercial Officer since August 2014. From June 2017 to December 2017, he served as our Head of Business Development. From August 2014 to June 2017, he served as our Senior Vice President and from July 2013 to August 2014, he served as our Vice President, Corporate Accounts. During his tenure as Chief Commercial Officer, he has led multiple product launches in the oncology market, delivering innovative cancer care. He has consistently inspired cross-functional teams to deliver superior performance to create value for Spectrum and restructured the commercial organization to advance our competitive advantage. Mr. Riga has over 20 years of pharmaceutical leadership experience. He has management experience in various positions at Wyeth Ayerst Pharmaceuticals, Eli Lilly and Company, Amgen Inc. and Dendreon Pharmaceuticals LLC. Throughout his career he integrated leadership and strategy to create meaningful value. His experience spans executive sales leadership, Six Sigma, marketing, manufacturing, and corporate accounts. Mr. Riga has obtained UCLA Corporate Governance Program Certification as a public company director.
As the Chief Operating Officer, Chief Commercial Officer a Executive Vice President of Spectrum Pharmaceuticals, the total compensation of Thomas Riga at Spectrum Pharmaceuticals is $3,817,960. There are 1 executives at Spectrum Pharmaceuticals getting paid more, with Joseph Turgeon having the highest compensation of $5,697,230.
Thomas Riga is 44, he's been the Chief Operating Officer, Chief Commercial Officer a Executive Vice President of Spectrum Pharmaceuticals since 2017. There are 13 older and no younger executives at Spectrum Pharmaceuticals. The oldest executive at Spectrum Pharmaceuticals, Inc. is Dolatrai Vyas, 76, who is the Independent Director.
Thomas's mailing address filed with the SEC is C/O CHIMERIX, INC., 2505 MERIDIAN PKWY, SUITE 100, DURHAM, NC, 27713.
Over the last 21 years, insiders at Spectrum Pharmaceuticals have traded over $34,101,027 worth of Spectrum Pharmaceuticals stock and bought 60,000 units worth $132,000 . The most active insiders traders include Rajesh C Md Shrotriya, Raymond W Cohen a Thomas J Riga. On average, Spectrum Pharmaceuticals executives and independent directors trade stock every 26 days with the average trade being worth of $68,584. The most recent stock trade was executed by Nora Brennan on 26 May 2023, trading 32,387 units of SPPI stock currently worth $35,626.
spectrum's core mission is to bring pharmaceutical products to patients for unmet medical needs. to this mission, we bring our years of drug development expertise, coupled with the insight of working in many different oncology indications. spectrum and its subsidiaries have six marketed oncology/hematology products, three for different types of non-hodgkins lymphoma, one for advanced metastatic colorectal cancer, one for a certain type of acute lymphoblastic leukemia (all) and one for multiple myeloma. there are two products in late-stage development, as well as a broad and diversified portfolio of proprietary drugs in various stages of development, all with a focus on oncology and hematology.
Spectrum Pharmaceuticals executives and other stock owners filed with the SEC include: